<unk>  is approved as a prescription for adults with type 2 diabetes mellitus poorly controlled by<unk>  or basal<unk>  alone. According to the American Diabetes Association, combination treatment of a GLP-1 receptor agonist with basal<unk>  should occur after HbA1C levels remain above target (7% for most type 2 people with diabetes) following use of basal<unk> . The use of<unk>  and<unk> -containing products is not recommended for use while pregnant. There is insufficient data in humans to form a pregnancy risk category for<unk> . Animal pregnancy studies have shown potential risks to the prenate, but it is unclear if these risks are related to the drug. It is unknown if<unk><unk>  and<unk>  are present in human milk or the effects these drugs would have on breastfed infants. Potential adverse effects to the mother and child as well as management of diabetes and glucose control should be considered prior to use of Soliqua during breastfeeding.
Insulin glargine/lixisenatide
Insulin degludec/liraglutide
Insulin degludec/insulin aspart
Insulin glulisine
NPH insulin
Glibenclamide/metformin
Insulin detemir
Lente insulin